WENZHOU, China, July 11, 2025 /PRNewswire/ -- GSP has marked the arrival of it's 40th anniversay with the rollout of its 300-millionth CV joint.
The milestone was marked with an official ceremony at its Wenzhou, China manufacturing facility.
This sets a new global benchmark for single-category automotive part production, says the company.
Executives and product leaders from Germany, the United States, Brazil, and other regions gathered to witness the occasion, which reflects GSP's four-decade journey from a single-product manufacturer to a global industry leader.
"The 300-millionth CV joint represents not just a number — it's a testament to the dedication of GSP employees and the trust placed in us by customers worldwide," said Richard Zhou, CEO of GSP Group, reflecting on the company's growth.
Daolun Zheng, Director of the Driveshaft Division and one of GSP's earliest employees, shared stories from the company's early days:
"When we launched our first CV joint, we personally visited over 20 countries, carrying samples and resolving 128 complex technical parameters over three years."
David Michaux, Director of Global Product Management explained how GSP got here: "Because GSP listens to GSP customers. It's 300 million times that our parts helped vehicles move, families travel safely, and customers trust our brand."
Today, GSP produces over 2.5 million CV joints monthly, with 49 patents, a 100% inspection rate, and several national certifications — including National Key New Products (2007, 2008, 2012) and National Torch Program Projects (2005, 2011). The company has also played a leading role in drafting four national industry standards, including JB/T 10189-2023 for constant velocity joints.
GSP's growth strategy evolved from a single-product focus to a full undercar parts ecosystem, including:
- Drive Shafts
- Hub Assemblies
- Shock Absorbers
- Rubber-to-Metal Components
- Steering & Suspension Parts
Through its AM + OE hybrid development model, GSP offers a one-stop solution with multi-category engineering integration and full-vehicle coverage.
The company's global operations — available in 11 languages — are powered by a dual commitment to Global Technical Excellence and Localized Precision Execution, enabling consistent quality and agile service across 120 countries.
With over 95% application coverage of mainstream vehicle models, GSP delivers OE-level quality and end-to-end service, including design, smart manufacturing, and after-sales support.
This precision-engineered component not only represents unmatched production capability, but also GSP's vision to fuel customer growth through innovation, reliability, and unmatched service.
About GSP Automotive Group:
GSP Automotive Group is a global leader in the design, manufacturing, and distribution of automotive driveline components, including CV axles, hub assemblies, loaded struts, and suspension solutions. With over 40 years of innovation and a commitment to quality-driven performance, GSP serves OEM and aftermarket customers across more than 120 countries. GSP combines advanced engineering, IATF-certified production, and a global supply chain to deliver trusted undercar solutions worldwide.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
GSP MARKS 40TH YEAR WITH 300 MILLIONTH CV JOINT
SYDNEY, Dec. 16, 2025 /PRNewswire/ -- Miroma Project Factory (MPF) has delivered a bespoke mobile solution for Screen2Quit, part of the International Lung Study trial and one of Australia's most ambitious research studies targeting smoking cessation in people undergoing lung cancer screening.
Commissioned by the Thoracic Research Centre at the University of Queensland and developed in partnership with Queensland Health, Screen2Quit is a revised, clinical version of the My QuitBuddy application redeveloped and instrumented to collect participant backend data for a multi-year randomised controlled trial (RCT). The goal: to determine whether app-based interventions can significantly outperform websites or control conditions in helping people quit smoking, still the leading cause of preventable disease worldwide.
From the outside, Screen2Quit looks and feels familiar to a smoking cessation application, but beneath the surface lies a purpose-built digital trial engine capable of tracking every interaction, from user-entered quit plans through scrolling and page navigation to community engagement, all while maintaining strict research integrity.
MPF's scope included native app development for both iOS and Android, and the creation of two secure backends. One backend supports community forum moderation, while the bespoke administration portal captures trial-specific analytics and fully anonymised data capture. Each app user is registered via a unique trial ID that gates access and ties in-session behaviour to anonymised clinical outcomes, enabling researchers to explore how digital behaviours relate to real-world smoking cessation.
"We're proud to help deliver a real-world health intervention that's not only scalable, but scientifically robust," said Jennifer Wilson, Founder and Futurist MPF. "Screen2Quit takes behaviour change out of the lab and into people's lives—with real data to back it."
The build was delivered in two structured phases:
- Phase 1 focused on core functionality: onboarding updates for trial enrollment, user navigation improvements, analytics configuration, regional localisation, and the creation of a trial-specific forum with moderator tools.
- Phase 2 added deeper analytics, forum download features, enhanced user activity logging, and infrastructure support for multi-jurisdiction deployment.
The app is deployed as part of the ILST (International Lung Screen Trial), which is funded by the NHMRC and supported by a cross-disciplinary clinical team. MPF continues to support the platform under a multi-year maintenance agreement, providing technical oversight, app store management, and hosting infrastructure for the duration of the trial.
About Screen2Quit (MQB UniQLD)
Screen2Quit is a clinical trial app developed for the International Lung Screen Trial, a multi-jurisdiction randomised controlled study coordinated by the University of Queensland Thoracic Research Centre. Based on the evidence-based My QuitBuddy app, Screen2Quit was redeveloped for use in clinical research, enabling detailed tracking of user behaviour and its relationship to smoking cessation outcomes. The app is only available to enrolled trial participants.
About Miroma Project Factory (MPF)
MPF is a multi-award-winning digital strategy and product studio that delivers innovative digital solutions across app, web, platforms, and systems. Specialising in purposeful technology, MPF works at the intersection of strategy, design, and engineering to create impactful digital products for organisations ready to lead. With deep expertise in healthcare, MPF helps clients scale responsibly, communicate clearly, and connect meaningfully with their audiences. For more information, visit www.theprojectfactory.com.
For media enquiries, interviews or partnership opportunities, please contact:
Miroma Project Factory
info@theprojectfactory.com
Henry Marshall
Thoracic Research Centre The University of Queensland
quit.research@health.qld.gov.au
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Miroma Project Factory: Powers Clinical-Grade App for One of Australia's Largest Smoking Cessation Trials
Miroma Project Factory: Powers Clinical-Grade App for One of Australia's Largest Smoking Cessation Trials
